Replies to post #5777 on Synaptogenix Inc (SNPX)

[InTheTrenches]

That is interesting pre-clinical data.

Biogen (BIIB) could get a 2-for-1 by partnering with Neurotrope on Bryostatin for Alzheimer's and Multiple Sclerosis:

https://www.benzinga.com/analyst-ratings/analyst-color/18/02/11216071/argus-downgrades-biogen-on-trial-delays-competition-in-

[Cyosol]

The thing that makes Bryostatin 1 so damn incredible to me is that since it enables the growth of new synapses, it single-handledly deals with the root problem that patients with several kinds of neurodegenerative disorders have, which is the loss of synapses.

This isn't just an Alzheimer's drug. It's a drug for repairing the central nervous system.